|
Getting your Trinity Audio player ready...
|
Ghana has partnered with German biotechnology company, BioNTech SE, to produce vaccines including Covid-19 vaccines.
The partnership also saw Rwanda and Senegal joining the collaboration to fill, finish, and package BioNTech mRNA vaccines in Africa, as a first step in the chain of domestic vaccine production which will to improve vaccine supply in Africa.
The announcement was made at a high-level meeting in Marburg, Germany, on Wednesday, 16th February 2022, where President Akufo-Addo, together with Presidents Macky Sall and Paul Kagame of Senegal and Rwanda respectively, witnessed the presentation of a BioNtech modular production facility solution for the production of mRNA vaccines in Africa.
The event was also attended President Ursula von der Leyen of the European Commission, and Tedros Adhanom Ghebreyesus, Director General of the World Health Organization.
Together with BioNTech’s CEO and Co-Founders Prof. Ugur Sahin and CMO, Prof. Özlem Türeci, and COO Dr. Sierk Poetting, they jointly discussed the infrastructural, regulatory and technological requirements to establish an end-to-end manufacturing network for mRNA-based vaccines in Africa.
BioNTech SE has introduced this approach to establish scalable vaccine production by delivering turnkey mRNA manufacturing facilities based on a container solution. At a high-level meeting at BioNTech’s manufacturing facility in Marburg, and at the invitation of kENUP Foundation, the company presented the container solution named “BioNTainer” to key partners of its efforts in Africa.
Describing the modular production facility as a “BioNTainer”, it will consist of one drug substance and one drug product module, each built of six ISO sized containers. They are clean rooms which BioNTech equips with state-of-the-art semi-automated manufacturing solutions.
Each module requires 800 sqm of space and offers an estimated capacity of several hundred of million doses of mRNA-based vaccines depending on the specific vaccine.
The BioNTainer will be equipped to manufacture a range of mRNA-based approved or authorized vaccines targeted to the needs of people in African Union member states, like BioNTech’s COVID-19 vaccine, and its malaria and tuberculosis vaccines, if they are successfully developed and approved.
The first BioNTainer is expected to be shipped to the African Union in mid-2022. BioNTech expects to ship BioNTainers to Rwanda and Senegal in close alignment with the respective country and the African Union. BioNTech will be responsible for the delivery and set-up of the modules, while local authorities and governments will ensure the needed infrastructure.
Ghana will support the manufacturing with fill-and-finish capacities. In cooperation with WHO, Africa CDC/AMA, and the European Union, BioNTech is supporting, identifying and setting up the necessary regulatory framework.
BioNTech will initially staff, own and operate the facilities to support the safe and rapid initiation of the production of mRNA-based vaccine doses. In the longer term the company plans to transfer manufacturing capacities and the know-how to local partners to enable sustainable production of mRNA vaccines in Africa. Vaccines manufactured in these facilities are expected to be dedicated to domestic use and export to other member states of the African Union at a not-for-profit price.
Speaking at the event, President Akufo-Addo indicated that the meeting heralds an important step in end-to-end vaccine manufacturing in Africa.
“This pan-African project fits very well into Ghana’s roadmap for vaccine development and manufacturing, developed by the Vaccine Manufacturing Committee, which I constituted nearly a year ago,” he said.
The President added, “We are willing to work together with our counterparts in Rwanda and Senegal to fill, finish, and package BioNTech mRNA vaccines, as a first step in the chain of domestic vaccine production.”
He told the gathering that Ghana’s Food and Drugs Authority (FDA), the principal Ghanaian regulatory agency, which is currently at WHO Maturity Level 3, and being upgraded to Maturity Level 4, will be readily available to work closely with regulatory bodies from the two (2) partner countries, to enhance the regulatory capacities for domestic vaccine development and manufacturing in Africa.
“We have gleaned a lot from this pandemic, and we are determined to enhance our ability to handle more efficiently any future outbreaks… We are ready to contribute and to be part of the manufacturing of mRNA COVID-19, Malaria and TB vaccines…” he added.
